- Home
- SIEB vs EPRX Comparison
SIEB vs EPRX Comparison
Compare SIEB & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- EPRX
- Stock Information
- Founded
- SIEB 1886
- EPRX 2011
- Country
- SIEB United States
- EPRX Canada
- Employees
- SIEB N/A
- EPRX N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- EPRX
- Sector
- SIEB Finance
- EPRX
- Exchange
- SIEB Nasdaq
- EPRX NYSE
- Market Cap
- SIEB 94.9M
- EPRX 111.1M
- IPO Year
- SIEB N/A
- EPRX N/A
- Fundamental
- Price
- SIEB $2.92
- EPRX $3.18
- Analyst Decision
- SIEB
- EPRX Strong Buy
- Analyst Count
- SIEB 0
- EPRX 1
- Target Price
- SIEB N/A
- EPRX $9.00
- AVG Volume (30 Days)
- SIEB 49.1K
- EPRX 24.6K
- Earning Date
- SIEB 11-12-2024
- EPRX 02-07-2025
- Dividend Yield
- SIEB N/A
- EPRX N/A
- EPS Growth
- SIEB 61.43
- EPRX N/A
- EPS
- SIEB 0.27
- EPRX N/A
- Revenue
- SIEB $83,357,000.00
- EPRX N/A
- Revenue This Year
- SIEB N/A
- EPRX N/A
- Revenue Next Year
- SIEB N/A
- EPRX N/A
- P/E Ratio
- SIEB $11.37
- EPRX N/A
- Revenue Growth
- SIEB 27.81
- EPRX N/A
- 52 Week Low
- SIEB $1.41
- EPRX $2.20
- 52 Week High
- SIEB $3.31
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- SIEB 50.58
- EPRX N/A
- Support Level
- SIEB $3.04
- EPRX N/A
- Resistance Level
- SIEB $3.25
- EPRX N/A
- Average True Range (ATR)
- SIEB 0.18
- EPRX 0.00
- MACD
- SIEB -0.03
- EPRX 0.00
- Stochastic Oscillator
- SIEB 13.04
- EPRX 0.00
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.